One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer.
Adding durvalumab and bevacizumab to a well-known therapeutic procedure boosted progression-free survival (PFS) by almost 7 months for eligible patients with unresectable hepatocellular carcinoma (uHCC), according to results being presented today.
Results from EMERALD-1, the trial evaluating use of the new treatment combination, are being presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), which is being held through tomorrow in San Francisco, California.
Transcatheter arterial chemoembolization (TACE), has been the current standard of care for 20 years for patients with uHCC who can receive embolization. The process involves targeting tumors by cutting off their blood supply while aiming chemotherapy directly at the tumor. About 20% to 30% of patients with uHCC, the most common liver cancer worldwide, can receive the treatment, according to ASCO.
Despite improvements in TACE over the years, recurrence is common, and experts including the lead author of EMERALD-1 have examined whether TACE itself “may create conditions that permit or even courage angiogenesis,” according to a review published in 2013. In particular, authors of EMERALD-1 write, “Embolization creates a proinflammatory tumor microenvironment and increases VEGF signals.”
Thus, investigators led by Riccardo Lencioni, MD, from the Pisa University School of Medicine in Pisa, Italy, evaluated using TACE in combination with other therapies that could reduce these effects.
“Research in other studies suggested that TACE would work well with 2 other types of anticancer therapy: immunotherapy, which attacks tumors using the immune system, and anti-VEGF therapy, which inhibits vascular endothelial growth factor (VEGF) – a protein which, when expressed in tumors, can promote blood flow to the tumor,” Lencioni said in a statement.
EMERALD-1 is a double-blind phase 3 study that enrolled 616 patients eligible for embolization to treat unresectable HCC. Patients were randomized in 3 groups: the first received the immune checkpoint inhibitor durvalumab (Imfinzi, AstraZeneca) plus the anti-VEGF bevacizumab and TACE (204 patients), the second received durvalumab plus TACE (207 patients), and third received TACE alone (205 patients). More than half the patients in the study (57.3%) had cancers in the intermediate stage, based on the Barcelona Clinic Liver Cancer (BCLC) staging system, which meant the liver had mild to moderate damage. Another 25.8% still had liver function, per BCLC, while 16.1% had severe liver damage.
The primary end point was PFS for the first group. Secondary end points included PFS for the other 2 groups, as well as overall survival (OS), objective response rate (ORR), time to progression (TTP), and safety for all 3 arms. End points besides safety were evaluated by blinded independent central review.
Key results were as follows:
Cathy Eng, MD, FACP, FASCO, who is professor of medicine, Division of Hematology and Oncology, Department of Medicine and is the co-director of GI Oncology and co-leader of the Gastrointestinal Cancer Research Program at Vanderbilt University Medical Center, said the results were encouraging.
“These results of the EMERALD-1 trial have the potential to establish a new standard of care for the treatment of unresectable hepatocellular carcinoma, a complex disease with poor prognosis, by showing for the first time that adding an immunotherapy-based combination to TACE significantly improved progression-free survival,” Eng said in a statement.
Reference
Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 18-20, 2024, San Francisco, CA. Abstract LBA432.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More